ak 2123 has been researched along with EHS Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kagiya, TV; Nair, CK; Rajagopalan, R | 1 |
| Devi, PU; Rao, BS | 1 |
2 other study(ies) available for ak 2123 and EHS Tumor
| Article | Year |
|---|---|
Radiosensitizer sanazole (AK-2123) enhances gamma-radiation-induced apoptosis in murine fibrosarcoma.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Cell Nucleus; DNA Fragmentation; Fibrosarcoma; Gamma Rays; Genome; Male; Mice; Neoplasm Transplantation; Neoplasms, Radiation-Induced; Nucleosomes; Radiation-Sensitizing Agents; Sarcoma, Experimental; Time Factors; Triazoles | 2003 |
Multimodality treatment using AK-2123, hydralazine, radiation & hyperthermia on a transplantable mouse tumour.
Topics: Animals; Combined Modality Therapy; Female; Hydralazine; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Sarcoma, Experimental; Triazoles; Vasodilator Agents | 1996 |